Search Results for "Colchicine And Rivaroxaban"

11:30 EDT 29th April 2017 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Rivaroxaban vs. Aspirin to Prevent Recurrent Venous Thromboembolism

In a 1-year study, rivaroxaban was more effective by several percentage points and did not confer excess bleeding risk.

Rivaroxaban for Postoperative DVT of the Lower Limb

Is rivaroxaban a safe and effective approach to postsurgical deep vein thrombosis after extended, but failed, warfarin therapy? Journal of Medical Case Reports

EINSTEIN CHOICE: Rivaroxaban Beats Aspirin for VTE Recurrence

Extended therapy with rivaroxaban at either 20 mg or 10 mg was more effective than aspirin at preventing recurrent venous thromboembolism without an increased risk of bleeding. Heartwire fro...

Rivaroxaban Doesn't Increase Post-ACS Bleeding vs Aspirin: Study

In GEMINI-ACS-1, bleeding risk did not differ significantly between patients on a P2Y12 inhibitor plus rivaroxaban vs aspirin. But is it really time to throw out aspirin as "the cornerstone"...

ACC.17: Rivaroxaban more effective in preventing VTE recurrence than aspirin, EINSTEIN CHOICE study shows

New research looking at the efficacy of r

Cancer patients may benefit from rivaroxaban to treat VTE

Cancer patients who received rivaroxaban (Xarelto) to treat venous thromboembolism (VTE) had significantly fewer emergency room visits and lower healthcare costs compared with those who received stand...

Rivaroxaban Promising Alternative to Fondaparinux for Superficial Vein Thrombosis

Oral rivaroxaban shows promise as a safe, effective, and less costly alternative to subcutaneous injections of fondaparinux to treat superficial vein thrombosis (SVT), according to industry-sponsored ...

Rivaroxaban reduces VTE recurrence compared with aspirin

In patients at elevated risk for a recurrence of potentially life-threatening blood clots, a low dose of the oral blood-thinning medication rivaroxaban reduced recurrences more than three-fold compare...

Matching PubMed Articles

Potential anticancer role of colchicine-based derivatives: an overview.

Colchicine, the main alkaloid of the poisonous plant meadow saffron (Colchicum autumnale L.), is a classical drug used for the treatment of gout and familial Mediterranean fever. Although colchicine i...

Colchicine for prevention and treatment of cardiac diseases: a meta-analysis.

Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the pre...

Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?

Rivaroxaban is an oral direct Xa inhibitor that can lead to prolongation of prothrombin time and activated partial thromboplastin time. However, these basic coagulation tests are not specific for the ...

Colchicine in Renal Medicine: New Virtues of an Ancient Friend.

Colchicine is a plant-derived alkaloid that disrupts the cell microtubule system and accumulates in neutrophils, inhibiting neutrophil adhesion and recruitment. Colchicine has been used extensively in...

Interleukin-8 enhances the effect of colchicine on cell death.

Pro-inflammatory cytokines are known to be generated in tumors and play important roles in angiogenesis, mitosis, and tumor progression. However, few studies have investigated the synergistic effects ...

Search Whole site using Google

Quick Search
Advertisement Advertisement